Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 220,535 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 220,535 shares of Vir Biotechnology stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $6.20, for a total value of $1,367,317.00. Following the transaction, the insider owned 15,119,959 shares in the company, valued at $93,743,745.80. This trade represents a 1.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Tuesday, October 21st, Endurance (Cayman) Ltd Svf sold 109,675 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.30, for a total value of $690,952.50.
• On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.10, for a total value of $78,348.40.
• On Wednesday, October 15th, Endurance (Cayman) Ltd Svf sold 16,671 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.07, for a total value of $101,192.97.
• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.08, for a total value of $13,984.00.
• On Thursday, October 9th, Endurance (Cayman) Ltd Svf sold 249,060 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.14, for a total value of $1,529,228.40.
• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total value of $2,820,764.10.
• On Tuesday, October 7th, Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.60, for a total value of $403,944.80.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.69, for a total value of $420,803.95.
• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.56, for a total value of $2,503,901.52.

Vir Biotechnology Price Performance

NASDAQ:VIR opened at $6.12 on Thursday. The stock has a market capitalization of $850.19 million, a PE ratio of -1.53 and a beta of 1.27. The business’s 50-day simple moving average is $5.27 and its 200-day simple moving average is $5.28. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, August 6th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The firm had revenue of $1.21 million during the quarter, compared to the consensus estimate of $2.38 million. Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The company’s revenue was down 60.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.02) EPS. On average, research analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in VIR. Raymond James Financial Inc. acquired a new position in shares of Vir Biotechnology during the 2nd quarter worth approximately $35,000. GAMMA Investing LLC increased its holdings in shares of Vir Biotechnology by 524.3% during the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock worth $46,000 after acquiring an additional 5,972 shares during the last quarter. Apollon Wealth Management LLC acquired a new position in shares of Vir Biotechnology during the 2nd quarter worth approximately $50,000. Daiwa Securities Group Inc. grew its holdings in Vir Biotechnology by 2,200.6% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock valued at $62,000 after buying an additional 11,773 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in Vir Biotechnology in the 2nd quarter valued at $63,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Analyst Upgrades and Downgrades

VIR has been the topic of several research reports. Bank of America upgraded Vir Biotechnology from a “neutral” rating to a “buy” rating and boosted their target price for the company from $12.00 to $14.00 in a research note on Wednesday, August 27th. Raymond James Financial initiated coverage on Vir Biotechnology in a research note on Friday, July 11th. They issued an “outperform” rating on the stock. Evercore ISI initiated coverage on Vir Biotechnology in a research note on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Vir Biotechnology in a research note on Monday, September 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Tuesday, October 14th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $17.30.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).